Current	0	7	O
prospects	8	17	O
for	18	21	O
controlling	22	33	O
cancer	34	40	B-Pathological_formation
growth	41	47	O
with	48	52	O
non	53	56	O
-	56	57	O
cytotoxic	57	66	O
agents	67	73	O
-	73	74	O
-	74	75	O
nutrients	75	84	O
,	84	85	O
phytochemicals	86	100	O
,	100	101	O
herbal	102	108	O
extracts	109	117	O
,	117	118	O
and	119	122	O
available	123	132	O
drugs	133	138	O
.	138	139	O

In	141	143	O
animal	144	150	O
or	151	153	O
cell	154	158	B-Cell
culture	159	166	O
studies	167	174	O
,	174	175	O
the	176	179	O
growth	180	186	O
and	187	190	O
spread	191	197	O
of	198	200	O
cancer	201	207	B-Pathological_formation
can	208	211	O
be	212	214	O
slowed	215	221	O
by	222	224	O
many	225	229	O
nutrients	230	239	O
,	239	240	O
food	241	245	O
factors	246	253	O
,	253	254	O
herbal	255	261	O
extracts	262	270	O
,	270	271	O
and	272	275	O
well	276	280	O
-	280	281	O
tolerated	281	290	O
,	290	291	O
available	292	301	O
drugs	302	307	O
that	308	312	O
are	313	316	O
still	317	322	O
rarely	323	329	O
used	330	334	O
in	335	337	O
the	338	341	O
clinical	342	350	O
management	351	361	O
of	362	364	O
cancer	365	371	B-Pathological_formation
,	371	372	O
in	373	375	O
part	376	380	O
because	381	388	O
they	389	393	O
seem	394	398	O
unlikely	399	407	O
to	408	410	O
constitute	411	421	O
definitive	422	432	O
therapies	433	442	O
in	443	445	O
themselves	446	456	O
.	456	457	O

However	458	465	O
,	465	466	O
it	467	469	O
is	470	472	O
reasonable	473	483	O
to	484	486	O
expect	487	493	O
that	494	498	O
mechanistically	499	514	O
complementary	515	528	O
combinations	529	541	O
of	542	544	O
these	545	550	O
measures	551	559	O
could	560	565	O
have	566	570	O
a	571	572	O
worthwhile	573	583	O
impact	584	590	O
on	591	593	O
survival	594	602	O
times	603	608	O
and	609	612	O
,	612	613	O
when	614	618	O
used	619	623	O
as	624	626	O
adjuvants	627	636	O
,	636	637	O
could	638	643	O
improve	644	651	O
the	652	655	O
cure	656	660	O
rates	661	666	O
achievable	667	677	O
with	678	682	O
standard	683	691	O
therapies	692	701	O
.	701	702	O

The	703	706	O
therapeutic	707	718	O
options	719	726	O
available	727	736	O
in	737	739	O
this	740	744	O
regard	745	751	O
include	752	759	O
measures	760	768	O
that	769	773	O
:	773	774	O
down	775	779	O
-	779	780	O
regulate	780	788	O
serum	789	794	O
free	795	799	O
IGF	800	803	B-Gene_or_gene_product
-	803	804	I-Gene_or_gene_product
I	804	805	I-Gene_or_gene_product
;	805	806	O
suppress	807	815	O
the	816	819	O
synthesis	820	829	O
of	830	832	O
mevalonic	833	842	B-Drug_or_compound
acid	843	847	I-Drug_or_compound
and	848	851	O
/	851	852	O
or	852	854	O
certain	855	862	O
derivatives	863	874	O
thereof	875	882	O
;	882	883	O
modulate	884	892	O
arachidonate	893	905	B-Drug_or_compound
metabolism	906	916	O
by	917	919	O
inhibiting	920	930	O
5	931	932	B-Gene_or_gene_product
-	932	933	I-Gene_or_gene_product
lipoxygenase	933	945	I-Gene_or_gene_product
,	945	946	O
12	947	949	B-Gene_or_gene_product
-	949	950	I-Gene_or_gene_product
lipoxygenase	950	962	I-Gene_or_gene_product
,	962	963	O
or	964	966	O
COX	967	970	B-Gene_or_gene_product
-	970	971	I-Gene_or_gene_product
2	971	972	I-Gene_or_gene_product
;	972	973	O
antagonize	974	984	O
the	985	988	O
activation	989	999	O
of	1000	1002	O
AP	1003	1005	B-Gene_or_gene_product
-	1005	1006	I-Gene_or_gene_product
1	1006	1007	I-Gene_or_gene_product
transcription	1008	1021	O
factors	1022	1029	O
;	1029	1030	O
promote	1031	1038	O
the	1039	1042	O
activation	1043	1053	O
of	1054	1056	O
PPAR	1057	1061	B-Gene_or_gene_product
-	1061	1062	I-Gene_or_gene_product
gamma	1062	1067	I-Gene_or_gene_product
transcription	1068	1081	O
factors	1082	1089	O
;	1089	1090	O
and	1091	1094	O
that	1095	1099	O
suppress	1100	1108	O
angiogenesis	1109	1121	O
by	1122	1124	O
additional	1125	1135	O
mechanisms	1136	1146	O
.	1146	1147	O

Many	1148	1152	O
of	1153	1155	O
these	1156	1161	O
measures	1162	1170	O
appear	1171	1177	O
suitable	1178	1186	O
for	1187	1190	O
use	1191	1194	O
in	1195	1197	O
cancer	1198	1204	B-Pathological_formation
prevention	1205	1215	O
.	1215	1216	O

